Company: ADPT
Filing Date: 2025-03-03
Form Type: 10-K
Source: 0000950170-25-030913
Chunk: 161

Company: Adaptive Biotechnologies Corp
Filing Date: 2025-03-03
Form: 10-K
Item: Item 1B
Chunk 161
---
 Other

    141

    172

    (19
    )

    Changes in operating assets and liabilities

    Accounts receivable, net

    (3,744
    )

    2,032

    (22,648
    )

    Inventory

    5,372

    (2,838
    )

    817

    Prepaid expenses and other current assets

    83

    (1,930
    )

    3,551

    Accounts payable and accrued liabilities

    671

    (5,407
    )

    7,111

    Operating lease right-of-use assets and liabilities

    (9,385
    )

    (8,676
    )

    (4,050
    )

    Deferred revenue

    (10,478
    )

    (29,291
    )

    (56,496
    )

    Other

    27

    (73
    )

    169

    Net cash used in operating activities

    (95,212
    )

    (156,324
    )

    (183,945
    )

    Investing activities

    Purchases of property and equipment

    (3,664
    )

    (10,697
    )

    (16,349
    )

    Purchases of marketable securities

    (244,257
    )

    (429,558
    )

    (278,778
    )

    Proceeds from maturities of marketable securities

    325,713

    569,902

    298,032

    Net cash provided by investing activities

    77,792

    129,647

    2,905

    Financing activities

    Proceeds from exercise of stock options

    241

    2,245

    7,890

    Proceeds from revenue interest purchase agreement, net of issuance costs

    —

    —

    124,375

    Net cash provided by financing activities

    241

    2,245

    132,265

    Net decrease in cash, cash equivalents and restricted cash

    (17,179
    )

    (24,432
    )

    (48,775
    )

    Cash, cash equivalents and restricted cash at beginning of year

    67,996

    92,428

    141,203

    Cash, cash equivalents and restricted